Cell and Gene Therapy Market to Surpass US$ 35.4 Billion by 2026 | Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer

Key players in the market are focused on launching novel cell and gene therapies, in order to treat various diseases and address the critical unmet needs of patients. For instance, in June 2011, Fibrocell Technologies, Inc. received approval from the U.S. Food and Drug Administration (FDA) for Azficel-T, which can be used for the treatment of nasolabial fold wrinkles.

Moreover, in November 2011, New York Blood Center, Inc. received approval from FDA for Hemacord. It is indicated for unrelated donor hematopoietic progenitor cell transplantation procedures and in patients with disorders affecting the hematopoietic system that are inherited, acquired, or results from myeloablative treatment in children. In October 2017, Kite Pharma received approval from the U.S. FDA for Yescarta (axicabtagene ciloleucel), which is used for the treatment of adults with large B-cell lymphoma. It was the first chimeric antigen receptor (CAR) T-cell therapy to receive FDA approval for large B-cell lymphoma.

Get Free Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2475

Browse 35 Market Data Tables and 28 Figures spread through 164 Pages and in-depth TOC on Cell and Gene Therapy Market, by Therapy Type (Cell Therapy and Gene Therapy), by Indication (Cardiovascular Disease, Cancer, Genetic Disorders, Infectious Diseases, Neurological Disorders, and Others), by Scale of Operation (In-house and Outsourced), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in June 2017, Johnson & Johnson acquired Actelion Ltd. Moreover, in October 2017, Gilead Sciences acquired Kite Pharma. Kite Pharma is involved in developing chimeric antigen receptor T-cell therapy, to recognize and attack malignant cells.

Key Takeaways of the Cell and Gene Therapy Market:
The global cell and gene therapy market is expected to exhibit a CAGR of 21.9% over the forecast period, owing to increasing prevalence of cardiovascular diseases, cancer, and neurological disorders
Among therapy type, the gene therapy segment held a dominant position in the cell and gene therapy market in 2018. For instance, in November 2018, Pharma Intelligence Company estimated that around 55% of the pipeline is of gene therapy, majorly medicines that are delivered by in vivo.

Among indication, cancer segment held a dominant position in the cell and gene therapy market in 2018, as majority of cell and gene therapies consist of cancer medicines in development stage
Key players operating in the global cell and gene therapy market include Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST

Get Free Request Sample Pages @ https://www.coherentmarketinsights.com/insight/request-sample/2475

Contact Us:
sales@coherentmarketinsights.com

U.S. Office:
Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
US flag US : +1-206-701-6702

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.